Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.98 |
---|---|
High | 19.18 |
Low | 12.81 |
Bid | 13.37 |
Offer | 13.38 |
Previous close | 21.97 |
Average volume | 14.02m |
---|---|
Shares outstanding | 98.28m |
Free float | 91.35m |
P/E (TTM) | -- |
Market cap | 2.16bn USD |
EPS (TTM) | -2.87 USD |
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
- Sarepta Therapeutics Provides Statement on ELEVIDYS
- Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
- U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
- Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
- Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
- Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
- Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
- Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
More ▼